GTT yields 84.75% · JNJ yields 2.13%● Live data
📍 GTT pulled ahead of the other in Year 1
Combined, GTT + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GTT + JNJ for your $10,000?
GTT Communications, Inc. provides cloud networking services to multinational enterprises, carriers, and government customers in the United States, Europe, and internationally. The company offers wide area networking, such as software-defined wide area networking, multiprotocol label switching, and virtual private LAN service; high bandwidth-Internet connectivity and IP transit, as well as broadband and wireless Internet access services; managed equipment and security services; and unified communication services consisting of session initiation protocol trunking, cloud unified communication service, and traditional analog voice. It also provides transport services, such as Ethernet services that enable to design network equipment; and video transport services to support broadcast quality transmission of live events, sports entertainment, and news to media and entertainment industry. In addition, the company offers infrastructure services enabling transport of high volume data between data centers, enterprise office locations, and media hubs; wavelength services to deliver scalable high-performance optical connectivity; colocation, turnkey, duct, and dark fiber services; advanced solutions, including security, hybrid cloud, database, and application management Its IP network consists of approximately 600 points of presence. GTT Communications, Inc. markets its products and services through a network of direct sales force and indirect sales channels. The company was formerly known as Global Telecom & Technology, Inc. and changed its name to GTT Communications, Inc. in January 2014. GTT Communications, Inc. was founded in 2005 and is headquartered in McLean, Virginia.
Full GTT Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.